Ishita Drugs & Industries discloses acquisition of 55 shares by related party Ishita Pharmaceuticals
On 19 June 2026, Ishita Pharmaceuticals bought 55 Rs10 equity shares of Ishita Drugs & Industries in an open‑market transaction, raising its holding to 32,697 shares (1.09% of total).
What Ishita Drugs & Industries announced
On 19 June 2026, Ishita Drugs & Industries Ltd filed a disclosure with BSE under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (Regulation 29(2)). The filing states that Ishita Pharmaceuticals – a related party of the target – acquired 55 equity shares of Rs 10 each in an open‑market transaction.
"Please take the above disclosure on record," the filing reads, confirming compliance with the regulatory requirement.
Details of the acquisition
- Acquirer: Ishita Pharmaceuticals (related party)
- Target: Ishita Drugs & Industries Ltd (BSE code 524400)
- Shares acquired: 55 shares, each with a face value of Rs 10
- Date of acquisition: 19 June 2026
- Mode of acquisition: Open market
- Pre‑acquisition holding: 32,642 shares (1.09% of total voting capital)
- Post‑acquisition holding: 32,697 shares (1.09% of total voting capital)
- Total equity share capital: Rs 29,903,000 (2,990,300 shares of Rs 10 each) – unchanged before and after the transaction.
The filing also confirms that there were no encumbrances, warrants, convertible securities, or other instruments involved in the deal.
Key facts at a glance
| Detail | Value |
|---|---|
| Company | Ishita Drugs & Industries Ltd |
| BSE ticker | 524400 |
| Filing date | 19 June 2026 |
| Regulation invoked | SEBI Regulation 29(2) (SAST) |
| Acquirer | Ishita Pharmaceuticals (related party) |
| Shares acquired | 55 shares (Rs 10 each) |
| Holding after acquisition | 32,697 shares (1.09% of total) |
| Mode of acquisition | Open market |
| Equity share capital | Rs 29.9 million (2,990,300 shares) |
Why this matters for investors
The disclosure is mandatory when a related party acquires shares that could affect control or voting dynamics. Although the 55‑share purchase is numerically small (0.00% of total share capital), it marginally increases the related party’s stake, keeping its overall holding at 1.09%. The transaction does not dilute existing shareholders because the total number of shares and the paid‑up capital remain unchanged. Investors should note the related‑party nature of the acquisition, as it may be relevant for corporate governance monitoring, but the filing does not indicate any change in management, strategy, or financial position.
Conclusion
Ishita Drugs & Industries has complied with SEBI’s disclosure requirements by reporting that its related party, Ishita Pharmaceuticals, purchased 55 shares on 19 June 2026, raising its holding to 32,697 shares (1.09%). The share capital and voting structure of the company remain unchanged, and no further regulatory approvals are indicated in the filing.
Frequently asked questions
Related stocks
Source filing: view original